Bevacizumab and ranibizumab: A matter of public interest

BMJ (Online)

Volumn 341, Issue 7764, 2010, Pages 114-

  Garattini, Silvio ^a   Bertele', Vittorio ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Drug Regulatory Policies Laboratory   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

DRUG EFFICACY; DRUG INDICATION; HUMAN; LETTER; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; MACULAR DEGENERATION;

EID: 77954627826     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c3721     Document Type: Letter

References (5)

1. Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 2010;340:c2459. (10 June.)[Abstract/Free Full Text]
2. Chakravarthy U. Bevacizumab for the treatment of neovascular age related macular degeneration. BMJ 2010;340:c2834. (9 June.)[Free Full Text]
3. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) vs ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol 2010;21:218-26.[CrossRef][Web of Science][Medline]
4. Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol 2009;148:875-82.[CrossRef][Web of Science][Medline]
5. Chang TS, Kokame G, Casey R, Prenner J, Feiner L, Anderson N. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration. Retina 2009;29:1235-41.[CrossRef][Web of Science][Medline]